Clinical trial · Observational
Tumor Feeding Vessels Deprivation Combined With Tyrosine Kinase Inhibitor in Liver Transplantation
The Value of Tumor Feeding Vessels Deprivation Combined With Tyrosine Kinase Inhibitor in Liver Transplantation
NCT05448339CI-TRIAL-00072860completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
To investigate the value of tumor feeding vessels deprivation combined with tyrosine kinase inhibitor in liver transplantation. Patients are enrolled into two groups according to the downstaging therapy they undergo before transplantion.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Liver Transplantation | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| PVHA or TACE | Combination Product | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- PVHA
- description
- Patients undergo tumor feeding vessels deprivation
- interventionNames
- Combination Product: PVHA or TACE
- label
- TACE
- description
- Patients undergo TACE therapy
- interventionNames
- Combination Product: PVHA or TACE
Primary outcomes (2)
- measure
- Underwent LT
- timeFrame
- January 2013 and December 2020
- description
- Underwent LT
- measure
- Successful downstaging
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 65 Years
Show eligibility criteria text
(1) age ≥18 years; (2) exceeding UCSF criteria; (3) absence of vascular invasion, nodal involvement, or extrahepatic metastases; (4) receiving TACE treatment or LTFVD treatment for downstaging purposes.
References
Publications (0)
Data not yet available
No reference posted for this study.